We observed a reduction of nuclear NFATc1 level in CLL B cells of ibrutinib-treated patients compared to that of the ibrutinib pretreated patients (Fig. 4B and Supplementary Fig. 8A). Here, NFATC1 is linked to B-cell chronic lymphocytic leukemia.